In this phase 3 trial that included patients who had been receiving stable SoC treatment and had biochemically controlled acromegaly at screening, those who received CAM2029 demonstrated significantly greater biochemical disease control, measured as IGF-1 and GH over 24 weeks, compared to placebo. The gene discussed is IGF1; the disease is acromegaly.